Relative adrenal insufficiency in adults with sickle cell disease

Relative adrenal insufficiency in adults with sickle cell disease

Eugene Sobngwi^1,2,&, Noel Désirée Mbango¹, Eric Vounsia Balti^1,3, Francoise Ngo Sack^1,4, Vicky Ama Moor², Jean-Claude Mbanya^1,2

 

¹Department of Internal Medicine, Endocrine and Diabetes Unit, Yaoundé Central Hospital, Yaoundé, Cameroon, ²Faculty of Medicine Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon, ³Faculty of Medicine and Pharmacy, Brussels Free University-VUB, Brussels, Belgium, ⁴Hematology and Oncology Unit, Yaoundé Central Hospital, Yaoundé, Cameroon

 

 

^&Corresponding author
Eugene Sobngwi, Department of Internal Medicine, Endocrine and Diabetes Unit, Yaoundé Central Hospital and Faculty of Medicine Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon

 

 

 

 

Sickle cell disease (SCD) is an autosomal recessive disease that results from a point mutation on the beta-globin molecule leading to erythrocyte rigidity and increased episodes of vaso-occlusive crisis [1]. Under precipitating conditions, red blood cell sequestration and hemolysis give rise to the clinical presentation of the disease mainly marked by anemia, pain and multi-organ ischemic damage [2]. Recurrence of vaso-occlusive episodes has been associated to cerebro-vascular ischemic events, renal damage, pulmonary ischemia and alteration of some endocrine functions in SCD [3,4]. Beside red blood cell sequestration and the resulting ischemia, the pathophysiology entails iron overload which has been associated to oxidative stress and multi-organ failure [5,6]. Previous studies have addressed the question of endocrine function in SCD [4]. Nevertheless, there is currently to the best of our knowledge, insufficient data on adrenal function in sickle cell patients, specifically in sub-Saharan Africa, the most affected part of the world with the highest SCD-related mortality. We therefore aimed in this study at investigating adrenal function of adult individuals with SCD in Cameroon.

 

 

Study population

 

Crisis-free adult (> 18 years old) patients with SCD were enrolled over a period of seven months (June-December 2007). The study was conducted in Yaoundé Central Hospital, one of the four tertiary reference hospitals in the capital city of Cameroon. Corticosteroid administration in the last three months preceding the investigation, recent infection, coagulopathy, thrombocytopenia, ongoing treatment including medications that could impact on adrenal function (anti-TB drugs, anti-epileptic therapy…) and recent episode of vaso-occlusive crisis were exclusion criteria. Age- and sex-matched healthy volunteers with normal hemoglobin genotype (HbAA) were recruited through advertisement among the general population as control individuals. Written informed consent was obtained from all participants. The study was approved by the institutional review board and the National Ethics Committee. Anthropometric and clinical data were collected via a standard questionnaire and clinical examination.

 

Assessment of adrenal function

 

Adrenal function was assessed after an overnight 12-hour fast. Blood sample was drawn from the antecubital vein prior to an IM injection of 0.25µg of tetracosactide (Synacthen® 0.25mg/ml, Sigma-tau, Rome, Italy) and 60 min after injection for assessment of plasma cortisol levels [7]. Cortisol levels were measured in duplicate by immuno-chemiluminescence (Immulite® 2000 Immunoassay System, Siemens, Los Angeles, CA, USA). The detection sensitivity of the method is 5.5 nmol/l and intra- / inter-assay coefficient of variation obtained from two series of samples analyzed daily in duplicate during 20 days were < 5%

 

Statistical analysis

 

Statistical differences between groups were determined by independent samples t-test or Wilcoxon’s rank test for continuous data and Fischer’s exact test in the case of categorical variables. The minimum required sample size (n = 8) was calculated to detect a 20% difference from a mean plasma cortisol level of 430.40 nmol/l. The chosen cut-off value for type I was 5% to reach an 80% power using 95% confidence interval (CI). The primary endpoint in this study was plasma cortisol level 60 min after stimulation and secondary endpoints include basal cortisol level, post-stimulatory incremental cortisol variation and cortisol fold increase. The post-stimulatory incremental cortisol variation (?cortisol) was estimated as the proportion of the difference between cortisol levels 60 min after stimulation and basal cortisol values. Statistical tests were performed two-tailed using SPSS for windows version 17.0 (SPSS, Chicago, IL, USA). Results with P value < 0.05 were considered significant.

 

 

Twenty crisis-free SCD patients and healthy volunteers were included in the study with a 1:1 ratio and a 60% proportion of male in each group. Systolic and diastolic blood pressure were similar in patients and controls while patients’ body fat composition tended to be lower in the presence of SCD (P = 0.080). Patients had on average 3 vaso-occlusive crises within the last twelve. SCD patients were significantly leaner than control individuals (P = 0.030). None of them had received a blood transfusion in the last 12 months. The characteristics of the study population are shown in Table 1. Although baseline cortisol levels were normal in all patients and comparable to healthy volunteers (286.9±79.1 vs. 263.6±64.7 nmol/L, P = 0.900). Patients’ mean post-stimulatory cortisol value was lower than control participants although the difference was not significant (P = 0.090). However, the incremental cortisol variation after tetracosactide stimulation was significantly lower in the presence of SCD (132.8 vs. 207.36, P = 0.047). Overall, five out of ten (50%) patients failed to achieve an optimal adrenal stimulation by reaching a two fold increase of basal plasma cortisol levels.

 

 

The findings suggest that relative adrenal insufficiency is not an infrequent event in crisis-free sickle cell patients. Although both basal and post-stimulatory cortisol levels were normal, the incremental cortisol variation was significantly lower in patients. Moreover, in the presence of SCD, the vast majority of participants failed to achieve significant increase in basal cortisol level after stimulation.

 

Based on our results patients with SCD are leaner than healthy controls. Because none of the patients had a recent intercurrent disease, the difference in BMI may solely be due to underlying metabolic changes due to the disease. In line with this, Borel et al. reported a 15% accretion of resting energy expenditure (REE) as well as an excess of protein breakdown in African-American patients with SCD compared to control in individuals [8]. Interestingly, the same excess of energy expenditure was observed in the presence of exogenous energy supply [9]. Moreover, even in the absence of crises, REE has been correlated with low-grade inflammation and oxidative stress in SCD [10]. This suggests that a higher energy and protein intake may not only correct the leaner body feature but could also reduce debilitating effects of iron-overload in sickle cell patients.

 

Furthermore, it is apparent that patients failed more often to double their cortisol levels after stimulation and the median increase in cortisol values was lower than in individual carrying normal hemoglobin genotype. Basal plasma cortisol level has previously been reported to be lower in SCD children compared to both individuals with HbAA and HbAS genotypes [11]. In fact, endocrine dysfunctions are known to be the most frequent event occurring in sickle cell anemia and the impairment occurs as a result of recurrent occlusion of small vessels but also as an outcome of oxidative stress mediated organ toxicity led by iron-overload [12]. Therefore, one would expect the level of organ damage - in the case of our study adrenal insufficiency - to be correlated with the frequency of blood transfusions. Although none of the patients described in our report received blood during the past 12 months, it is worth mentioned that included individuals were above age 18; thus the observed relative adrenal insufficiency could occur as an outcome of chronic insidious hemolytic events and oxidative stress due to gradual iron accumulation [5,6].

 

The limitations of our study include the small sample size; although appropriate and well powered, a bigger study population may have enhanced the magnitude of estimates. Also, we do not report on basal plasma ACTH levels that could reveal the primary or secondary origin of the adrenal function impairment; 3. The proportion of SS hemoglobin in patients has not been assessed; this may have given some clues on the association with the frequency of vaso-occlusion events thus aid in understanding the relationship with the resulting adrenal insufficiency [1]. Finally we lack data on markers of oxidative stress and iron-overload to show the association with the low BMI observed in our study population. This is however a broader scope than what was foreseen by this study. Despite these limitations, we performed a stimulatory test which is a strong asset worth noticed.

 

 

Our findings suggest that relative adrenal insufficiency is not a rare event in crisis-free adult patients with SCD. We believe that this study may pave the way to further investigations of adrenal function during vaso-occlusive crisis and to subsequent studies aiming at unraveling the interplay between iron-overload, acute low-grade inflammation, oxidative stress and adrenal insufficiency in SCD patients in the presence or not of vaso-occlusive events.

 

 

The authors declare no competing interests.

 

 

All authors have read and agreed to the final manuscript.

 

 

Table 1: general characteristics and adrenal function of the study population

 

 

1. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010 Dec 11;376(9757):2018-3 Epub 2010 Dec 3. PubMed | Google Scholar


2. Malowany JI, Butany J. Pathology of sickle cell disease. Semin Diagn Pathol. 2012 Feb;29(1):49-55. PubMed | Google Scholar


3. Manci EA, Culberson DE, Yang YM et al. Causes of death in sickle cell disease: an autopsy study. Br J Haematol. 2003 Oct;123(2):359-65. PubMed | Google Scholar


4. el-Hazmi MA, Bahakim HM, al-Fawaz I. Endocrine functions in sickle cell anaemia patients. J Trop Pediatr. 1992 Dec;38(6):307-13. PubMed | Google Scholar


5. Walter PB, Fung EB, Killilea DW et al. Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol. 2006; 135:254-263. PubMed | Google Scholar


6. Nur E, Biemond BJ, Otten HM et al. Oxidative stress in sickle cell disease; pathophysiology and potential implications for disease management. Am J Hematol. 2011;86:484-489. PubMed | Google Scholar


7. Dorin RI, Qualls CR, Crapo LM. Diagnosis of adrenal insufficiency. Ann Intern Med. 2003 Aug 5;139(3):194-204. PubMed | Google Scholar


8. Borel MJ, Buchowski MS, Turner EA et al. Alterations in basal nutrient metabolism increase resting energy expenditure in sickle cell disease. Am J Physiol. 1998; 274:E357-E364. PubMed | Google Scholar


9. Borel MJ, Buchowski MS, Turner EA et al. Protein turnover and energy expenditure increase during exogenous nutrient availability in sickle cell disease. Am J Clin Nutr. 1998 Sep;68(3):607-14. PubMed | Google Scholar


10. Akohoue SA, Shankar S, Milne GL et al. Energy expenditure, inflammation and oxidative stress in steady-state adolescents with sickle cell anemia. Pediatr Res. 2007 Feb;61(2):233-8. PubMed | Google Scholar


11. Osifo BO, Lukanmbi FA, Adekile A. Plasma cortisol in sickle cell disease. Acta Haematol. 1988;79(1):44-5. PubMed | Google Scholar


12. Smiley D, Dagogo-Jack S, Umpierrez G. Therapy insight: metabolic and endocrine disorders in sickle cell disease. Nat Clin Pract Endocrinol Metab. 2008;4:102-109. PubMed | Google Scholar